Published in
American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(36), p. 9025-9025
DOI: 10.1200/jco.2018.36.15_suppl.9025
Links
Tools
A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.
Journal article published in 2018 by
Jonathan Wade Goldman,
Julien Mazieres,
Fabrice Barlesi,
Marianna Koczywas,
Konstantin H. Dragnev,
Tuncay Göksel,
Alexis B. Cortot,
Nicolas Girard,
Claas Wesseler 
,
Helge Bischoff,
Ernest Nadal,
Keunchil Park,
Shun Lu,
Alvaro Taus,
Manuel Cobo
and other authors.
,
Helge Bischoff,
Ernest Nadal,
Keunchil Park,
Shun Lu,
Alvaro Taus,
Manuel Cobo
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 